AVIR on Nasdaq
Atea Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with MannKind Corporation, Arcutis Biotherapeutics, Inc. or Sinovac Biotech, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2021
39.4%Operating margin3
34.5%Net margin3
622.5%Revenue growth, 20213
17.1%Return on equity4
-$87.0MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2021
- Research and development48¢$167.2M
- Other costs13¢$45.6M
- Income tax5¢$17.4M
- Profit34¢$121.2M
Out of $351.4M in revenue.3
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $148.0M | $144.1M |
| General and administrative | $32.9M | $48.8M |
| Total operating expenses | $180.9M | $192.9M |
| Loss from operations | -$180.9M | -$192.9M |
| Interest income and other, net | $16.4M | $25.5M |
| Loss before income taxes | -$164.5M | -$167.5M |
| Income tax benefit (expense) | $6.2M | -$925.0K |
| Net loss | -$158.3M | -$168.4M |
| Unrealized (loss) gain on available-for-sale investments | -$59.0K | $26.0K |
| Comprehensive loss | -$158.4M | -$168.4M |
| Net loss per share - basic | -$1.94 | -$2.00 |
| Net loss per share - diluted | -$1.94 | -$2.00 |
| Weighted-average number of common shares - basic | 81.5M shares | 84.3M shares |
| Weighted-average number of common shares - diluted | 81.5M shares | 84.3M shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $95.7M | $64.7M | |
| Marketable securities | $206.1M | $390.0M | |
| Prepaid expenses and other current assets | $9.2M | $7.6M | |
| Total current assets | $311.0M | $462.4M | |
| Property and equipment, net | $457.0K | $873.0K | |
| Other assets | $3.1M | $197.0K | |
| Operating lease right-of-use assets, net | $634.0K | $1.2M | |
| Total assets | $315.2M | $464.7M | |
| Accounts payable | $12.9M | $4.5M | |
| Accrued expenses and other current liabilities | $26.0M | $13.3M | |
| Current portion of operating lease liabilities | $843.0K | $800.0K | |
| Total current liabilities | $39.8M | $18.6M | |
| Operating lease liabilities | $0 | $842.0K | |
| Income taxes payable | $0 | $6.4M | |
| Total liabilities | $39.8M | $25.8M | |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 78,126,796 and 84,463,059 shares issued and outstanding as of December 31, 2025 and 2024 | $78.0K | $84.0K | |
| Additional paid-in capital | $797.8M | $802.8M | |
| Accumulated other comprehensive gain | $174.0K | $233.0K | |
| Accumulated deficit | -$522.6M | -$364.2M | |
| Total stockholders equity | $275.4M | $438.9M | $555.2M |
| Total liabilities and stockholders equity | $315.2M | $464.7M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 78.1M shares | 84.5M shares | |
| Common stock, shares outstanding | 78.1M shares | 84.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$158.3M | -$168.4M |
| Stock-based compensation expense | $20.7M | $51.8M |
| Depreciation and amortization expense | $416.0K | $416.0K |
| Accretion of premium and discounts on marketable securities | -$4.9M | -$11.8M |
| Income tax benefit | -$6.4M | $0 |
| Prepaid expenses and other current assets | -$1.5M | $5.9M |
| Other assets | -$2.9M | $0 |
| Accounts payable | $8.5M | $206.0K |
| Accrued expenses and other liabilities | $12.7M | -$13.4M |
| Operating lease liabilities | -$190.0K | -$175.0K |
| Net cash used in operating activities | -$132.0M | -$135.5M |
| Purchases of marketable securities | -$281.9M | -$461.2M |
| Sales and maturities of marketable securities | $470.7M | $517.3M |
| Net cash provided by investing activities | $188.8M | $56.1M |
| Proceeds from issuance of common stock under ESPP | $201.0K | $267.0K |
| Proceeds from issuance of common stock upon option exercise | $58.0K | $0 |
| Stock repurchase | -$25.5M | $0 |
| Cash paid for taxes in connection with RSU and PSU vesting | -$485.0K | $0 |
| Net cash (used in) provided by financing activities | -$25.7M | $267.0K |
| Net increase (decrease) in cash and cash equivalents | $31.0M | -$79.1M |
Recent filings
- Oct 6, 2026SCHEDULE 13G
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 22, 20268-K
- May 21, 20264/A
- May 20, 20264
- May 12, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9